3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
NET
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Breast
1
Conditions
Colorectal Neoplasms
62
Carcinoma, Hepatocellular
25
Neoplasm Metastasis
15
Rectal Neoplasms
11
Colonic Neoplasms
10
Gastrointestinal Stromal Tumors
9
Sarcoma
6
Ovarian Neoplasms
5
Osteosarcoma
5
Glioblastoma
5
Cholangiocarcinoma
5
Stomach Neoplasms
4
Melanoma
4
Liver Neoplasms
4
Sarcoma, Ewing
3
Pancreatic Neoplasms
3
Neoplasms
3
Leukemia, Myeloid, Acute
3
Esophageal Neoplasms
3
Colorectal Cancer Metastatic
3
Carcinoma, Non-Small-Cell Lung
3
Thyroid Neoplasms
2
Rhabdomyosarcoma
2
Myelodysplastic Syndromes
2
Multiple Myeloma
2
Mesothelioma, Malignant
2
Lymphoma, Non-Hodgkin
2
Hematologic Neoplasms
2
Hemangiosarcoma
2
Gastrointestinal Neoplasms
2
Interventions
tazemetostat
1
relatlimab
1
regorafenib
1
durvalumab
1
brigimadlin
1
bintrafusp alfa protein, human
1
Nivolumab
1
Doxorubicin
1
Clinical Trials, Phase II as Topic
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Tertiary Lymphoid Structures
×
regorafenib
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled